Suchen
Drugs Made In America Acquisition II Ord Shs
DMIIZur Watchlist hinzufügen
10.010USD
-0.010-0.10%
Handelsschluss 05/08, 16:00（ET）Kurse um 15 Minuten verzögert
637.64MMarktkapitalisierung
31.77KGV TTM
mehr Informationen über Drugs Made In America Acquisition II Ord Shs Unternehmen
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to search for business combination targets in the pharmaceutical industry. The Company is neither engaged in any operations nor generated any revenues.
Drugs Made In America Acquisition II Ord Shs Informationen
BörsenkürzelDMII
Name des UnternehmensDrugs Made In America Acquisition II Corp
IPO-datumSep 25, 2025
CEOStockwell (Lynn)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
Geschäftsjahresende- -
Addresse1 East Broward Boulevard
StadtFT LAUDERDALE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl33301
Telefon19548703099
Website
BörsenkürzelDMII
IPO-datumSep 25, 2025
CEOStockwell (Lynn)
Führungskräfte von Drugs Made In America Acquisition II Ord Shs
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, Feb 19
Aktualisiert: Thu, Feb 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Drugs Made In America Acquisition II LLC
4.64%
Magnetar Capital Partners LP
4.24%
Glazer Capital, LLC
3.69%
First Trust Capital Management L.P.
3.25%
Conaway (Charles C.)
3.14%
Andere
81.04%
Aktionäre
Aktionäre
Anteil
Drugs Made In America Acquisition II LLC
4.64%
Magnetar Capital Partners LP
4.24%
Glazer Capital, LLC
3.69%
First Trust Capital Management L.P.
3.25%
Conaway (Charles C.)
3.14%
Andere
81.04%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
29.83%
Investment Advisor/Hedge Fund
16.78%
Investment Advisor
8.57%
Individual Investor
8.48%
Corporation
6.74%
Pension Fund
2.12%
Research Firm
1.24%
Bank and Trust
0.20%
Andere
26.04%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q4
1
666.67K
0.00%
--
2026Q1
58
37.42M
58.75%
+33.66M
2025Q4
7
3.04M
4.64%
+3.04M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Drugs Made In America Acquisition II LLC
4.83M
7.37%
+4.83M
--
Dec 03, 2025
Magnetar Capital Partners LP
2.70M
4.12%
+2.70M
--
Dec 31, 2025
Glazer Capital, LLC
2.35M
3.58%
+2.35M
--
Dec 31, 2025
First Trust Capital Management L.P.
2.07M
3.15%
+2.07M
--
Dec 31, 2025
Conaway (Charles C.)
2.00M
3.05%
+2.00M
--
Dec 03, 2025
Hudson Bay Capital Management LP
1.97M
3%
+1.97M
--
Dec 31, 2025
Wolverine Asset Management, LLC
1.06M
1.62%
+1.06M
--
Dec 31, 2025
Tenor Capital Management Co., L.P.
1.50M
2.29%
+1.50M
--
Dec 31, 2025
Polar Asset Management Partners Inc.
1.50M
2.29%
+1.50M
--
Dec 31, 2025
Millennium Management LLC
1.50M
2.29%
+1.50M
--
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
